Anaplerotic therapy of huntington disease and other polyglutamine diseases

Abstract

The present invention relates to a method for treating and/or preventing Huntington disease and other polyglutamine diseases, comprising the step of administering an effective amount of a precursor of propionyl-CoA to an individual in need thereof.

1 . A method of treating and/or preventing a polyglutamine disease in a patient, the method comprising administering to the patient a composition comprising a precursor of propionyl-CoA. 
     
     
         2 . The method of  claim 1 , wherein the polyglutamine disease is Huntington disease. 
     
     
         3 . The method of  claim 1 , wherein the precursor of propionyl-CoA is selected from the group consisting of odd-medium-chain fatty acids, seven-carbon fatty acid, triheptanoin, heptanoate, C5 ketone bodies, 3-ketovalerate and 3-hydroxyvalerate. 
     
     
         4 . The method of  claim 1 , wherein the precursor of propionyl-CoA is triheptanoin, heptanoic acid or heptanoate. 
     
     
         5 . The method of  claim 1 , wherein the precursor of propionyl-CoA is triheptanoin. 
     
     
         6 . The method of  claim 1 , wherein the precursor of propionyl-CoA is administered to the patient via ingestion of a food substance containing said precursor.